Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from ADMA Biologics ( (ADMA) ).
On March 27, 2026, ADMA Biologics issued a detailed rebuttal to a March 24, 2026 short-seller report from Culper Research, rejecting allegations about artificial demand creation, channel stuffing and mischaracterization of ASCENIV’s competitive position. The company presented partner-sourced data showing steady, record-high ASCENIV demand over the past two-plus years and inventory days-on-hand for ASCENIV and BIVIGAM that it says are consistent with industry norms and necessary safety-stock levels for immune-compromised patients requiring regular IVIG therapy.
ADMA argued that the report misunderstands ASCENIV’s role as a late-line, premium-priced therapy for patients who fail standard immune globulin treatments, and therefore overstated competitive pressures from more routine IVIG products. It also highlighted unqualified audit opinions from a Big Four accounting firm for fiscal years 2024 and 2025, explained that its prior auditor left due to a private equity acquisition, and denied ever engaging in undisclosed related-party transactions involving its immune globulin products, aiming to reassure investors about its governance and financial reporting integrity.
The most recent analyst rating on (ADMA) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.
Spark’s Take on ADMA Stock
According to Spark, TipRanks’ AI Analyst, ADMA is a Neutral.
The score is supported by strong underlying fundamentals (revenue/margin expansion and improved leverage) and positive corporate actions (accelerated buyback and growth targets). The biggest drag is sharply bearish technicals with the stock well below key moving averages, alongside a mid-to-high P/E and no dividend to cushion volatility.
To see Spark’s full report on ADMA stock, click here.
More about ADMA Biologics
ADMA Biologics, Inc. is a U.S.-based, end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty biologics, particularly plasma-derived immune globulin products. Its portfolio includes ASCENIV, an FDA-approved intravenous immune globulin indicated for primary humoral immunodeficiency, and BIVIGAM, targeting immune-compromised patients at risk for infectious diseases.
Average Trading Volume: 4,291,314
Technical Sentiment Signal: Sell
Current Market Cap: $1.97B
Find detailed analytics on ADMA stock on TipRanks’ Stock Analysis page.